SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Heightened inflammatory response is a prominent feature of severe COVID-19 disease. We report that the SARS-CoV-2 ORF3a viroporin activates the NLRP3 inflammasome, the most promiscuous of known inflammasomes. Ectopically expressed ORF3a triggers IL-1β expression via NFκB, thus priming the inflammasome. ORF3a also activates the NLRP3 inflammasome but not NLRP1 or NLRC4, resulting in maturation of IL-1β and cleavage/activation of Gasdermin. Notably, ORF3a activates the NLRP3 inflammasome via both ASC-dependent and -independent modes. This inflammasome activation requires efflux of potassium ions and oligomerization between the kinase NEK7 and NLRP3. Importantly, infection of epithelial cells with SARS-CoV-2 similarly activates the NLRP3 inflammasome. With the NLRP3 inhibitor MCC950 and select FDA-approved oral drugs able to block ORF3a-mediated inflammasome activation, as well as key ORF3a amino acid residues needed for virus release and inflammasome activation conserved in the new variants of SARS-CoV-2 isolates across continents, ORF3a and NLRP3 present prime targets for intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016 · cited 2×
“, 2011) are at greater risk for severe disease (Richardson et al., 2020; Wu and McGoogan, 2020; Yang et al., 2020), ii) viroporins expressed by the closely-related SARS-CoV activate the NLRP3 inflammasome (Chen et al.”
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y., & Zhou, Y. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.03.017 · Cited by 4,206 · cited 1×
“, 2011) are at greater risk for severe disease (Richardson et al., 2020; Wu and McGoogan, 2020; Yang et al., 2020), ii) viroporins expressed by the closely-related SARS-CoV activate the NLRP3 inflammasome (Chen et al.”
Inflammasomes: mechanism of assembly, regulation and signalling
Broz, P., & Dixit, V. M. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.58 · Cited by 3,500
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, K., Philippot, Q., Rosain, J., Béziat, V., et al. (2020) · Science · doi:10.1126/science.abd4585 · Cited by 2,662
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I. K. D., Hodeib, S., Korol, C., et al. (2020) · Science · doi:10.1126/science.abd4570 · Cited by 2,229
Multiorgan and Renal Tropism of SARS-CoV-2
Puelles, V. G., Lütgehetmann, M., Lindenmeyer, M. T., Sperhake, J. P., Wong, M. N., Allweiss, L., Chilla, S., Heinemann, A., Wanner, N., Liu, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2011400 · Cited by 1,775 · cited 1×
“With lung as the predominant site of pathology along with established tropism for kidney and other organs (Puelles et al., 2020), we introduced ORF3a into lung origin A549 cells and for comparison, kidney origin HEK-293T cells, cell types that support SARS-CoV-2 infection (Hoffmann et al.”
Viral dynamics in mild and severe cases of COVID-19
Liu, Y., Yan, L.-M., Wan, L., Xiang, T.-X., Le, A., Liu, J.-M., Peiris, M., Poon, L. L. M., & Zhang, W. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30232-2 · Cited by 1,727 · cited 1×
“Indeed, during the second week of illness, many individuals experience an inflammatory surge that can herald severe disease (Liu et al., 2020; Mehta et al., 2020).”
NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux
He, Y., Zeng, M. Y., Yang, D., Motro, B., & Núñez, G. (2016) · Nature · doi:10.1038/nature16959 · Cited by 1,295 · cited 1×
“The following primers were used for amplifying the IL-1β promoter: forward primer 5′AGGAGTAGCAAACTATGACAC3′ and reverse primer 5′ACGTGGGAAAATCCAGTATTT3’ (Hiscott et al., 1993).”
Rodrigues, T. S., de Sá, K. S. G., Ishimoto, A. Y., Becerra, A., Oliveira, S., Almeida, L., Gonçalves, A. V., Perucello, D. B., Andrade, W. A., Castro, R., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201707 · Cited by 839
Inflammasome is a central player in the induction of obesity and insulin resistance
Stienstra, R., van Diepen, J. A., Tack, C. J., Zaki, M. H., van de Veerdonk, F. L., Perera, D., Neale, G. A., Hooiveld, G. J., Hijmans, A., Vroegrijk, I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100255108 · Cited by 727
Inflammasome formation in the lungs of patients with fatal COVID-19
Toldo, S., Bussani, R., Nuzzi, V., Bonaventura, A., Mauro, A. G., Cannatà, A., Pillappa, R., Sinagra, G., Nana-Sinkam, P., Sime, P., et al. (2021) · Inflammation Research · doi:10.1007/s00011-020-01413-2 · Cited by 132
Nlrp3 Inflammasome Activation in Type 2 Diabetes: Is It Clinically Relevant?
Dixit, V. D. (2013) · Diabetes · doi:10.2337/db12-1115 · Cited by 85 · cited 2×
“…such as diabetes, atherosclerosis, and obesity (all pro-inflammatory conditions marked by NLRP3 activation) (Chen et al., 2017; Dixit, 2013; Grant; Dixit, 2013; Jin and Fu, 2019; Rheinheimer et al., 2017; Stienstra et al., 2011) are at greater risk for severe disease (Richardson et al.,…”
Cited by
Innate immunity: the first line of defense against SARS-CoV-2
Diamond, M. S., & Kanneganti, T.-D. (2022) · Nature Immunology · doi:10.1038/s41590-021-01091-0 · Cited by 618
Inflammasome activation in infected macrophages drives COVID-19 pathology
Sefik, E., Qu, R., Junqueira, C., Kaffe, E., Mirza, H., Zhao, J., Brewer, J. R., Han, A., Steach, H. R., Israelow, B., et al. (2022) · Nature · doi:10.1038/s41586-022-04802-1 · Cited by 529
Pyroptosis-Induced Inflammation and Tissue Damage
Vasudevan, S. O., Behl, B., & Rathinam, V. A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101781 · Cited by 412
Inflammasome activation at the crux of severe COVID-19
Vora, S. M., Lieberman, J., & Wu, H. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00588-x · Cited by 325
Clough, E., Inigo, J., Chandra, D., Chaves, L., Reynolds, J. L., Aalinkeel, R., Schwartz, S. A., Khmaladze, A., & Mahajan, S. D. (2021) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-021-10015-6 · Cited by 75
Metadata
- Authors
- Xu, H., Akinyemi, I. A., Chitre, S. A., Loeb, J. C., Lednicky, J. A., McIntosh, M. T., & Bhaduri-McIntosh, S.
- Venue
- Virology
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 568
- Pages
- 13-22
- ISSN
- 0042-6822 (ISSN-L)
- OpenAlex
- W4205454043
- Cited by
- 176
- References
- 14
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.